Ex vivo susceptibility to antimalarial drugs and polymorphisms in drug resistance genes of African Plasmodium falciparum, 2016-2023: a genotype-phenotype association study

Evidence before this study Artemisinin-based combination therapies (ACTs) have been introduced since the 2000s as the first-line curative treatment of malaria. ACTs combine an artemisinin derivative, which rapidly reduces parasite load, with another antimalarial drug –known as partner drug-which eliminates the remaining parasites thanks to its longer half-life. This approach reduces the likelihood of parasites developing resistance to both drugs, thereby increasing treatment efficacy and delaying the emergence of resistance. However, resistance to artemisinins and then to some partner drugs was identified in Southeast Asia more than a decade ago and has spread throughout the region. Artemisinin partial resistance is now emerging in the East and Horn of Africa. It manifests as delayed parasite clearance from the bloodstream after treatment, increasing the parasite load in contact with the partner drug only and the likelihood of selecting resistant parasites. It is, therefore, important to monitor antimalarial drug susceptibility and drug resistance mutations in contemporary African isolates, especially in the understudied West and Central African regions, to anticipate the spread of multidrug-resistant parasites.

We searched for articles on antimalarial drug resistance published between January 1, 2000, and July 1, 2024, using the PubMed search terms “antimalarial resistance”, “Africa”, and “ex vivo”. Of the 69 published studies, only six encompassing a total of 827 isolates across five West and Central African countries from 2016 to 2022 combined ex vivo drug assays with genotyping data. Parasites with an increased rate of ex vivo survival to artemisinins were reported in one study from Ghana (7/90 isolates in 2018) and another from The Gambia (4/41 isolates in 2017). Only the Ghanaian study reported mutations in the non-propeller domain of pfkelch13 gene, whereas the Gambian study reported mutations associated with reduced susceptibility to lumefantrine (7%, 3/41). In Mali, Senegal and Burkina Faso, most isolates were susceptible to commonly used antimalarial drugs (chloroquine, amodiaquine, piperaquine, mefloquine, lumefantrine and dihydroartemisinin) using standard growth inhibition assays. In Ghana, reduced susceptibility to artemisinin, mefloquine and amodiaquine was observed. The relative lack of recent data on parasite susceptibility to antimalarial drugs in recent parasites from West and Central Africa prompted us to conduct this study.

Added value of this study Ex vivo susceptibility to six antimalarial drugs (dihydroartemisinin, lumefantrine, mefloquine, chloroquine, monodesethylamodiaquine, and piperaquine) and mutations in fourteen drug resistance genes were evaluated in 805 isolates collected between January 2016 and February 2023 from 35 African countries, mainly from West and Central Africa.

Median IC₅₀ values were in the low nanomolar range, indicating good potency against P. falciparum. However, worrying trends emerged from 2019 onwards, with median IC₅₀ values for lumefantrine that increased from 13·9 nM in 2016-18 to 23 nM in 2019-23 and for amodiaquine from 20·3 nM to 35·4 nM.

The high prevalence of resistance alleles in pfdhfr, pfdhps, pfmdr1 and pfcrt genes underscores the sustained pressure exerted by antimalarial drugs on parasite populations. Notably, although the triple mutant pfdhfr N51I-C59R-S108N was highly prevalent, the dhfr-dhps quintuple mutant (with extra pfdhps A437G-K540E), which is responsible for sulfadoxine-pyrimethamine treatment failure in adults and children, was rare. In addition, the analysis revealed some geographic and temporal variations in mutation prevalence.

The genotype-phenotype association analysis performed in this study elucidates the relationship between genetic variants and ex vivo drug susceptibility, providing valuable information for understanding the molecular basis of resistance and informing future treatment strategies. For example, mutations in the pfcrt and pfmdr1 genes, mainly K76T and N86Y, were associated with altered susceptibilities to most drugs. Haplotypic association analysis further indicated that the two genes have cumulative effects on the susceptibility to lumefantrine, with the wild-type haplotype (pfcrt K76-pfmdr1 N86) exhibiting the least susceptibility.

Implication of all the available evidence While the susceptibility to most antimalarials suggests continued efficacy, the observed decrease in susceptibilities to lumefantrine and amodiaquine in parasites from West and Central Africa from 2019 onwards suggests an ongoing adaptation of parasites, possibly related to the increasing use of ACT treatments in Sub-saharan Africa since a decade. These phenotypic changes over time were accompanied by small changes in the prevalence of resistance alleles in pfcrt and pfmdr1 genes. Additional changes, potentially leading to larger decreases in drug susceptibilities, can be expected over time. The large-scale analysis presented here provides invaluable, contemporary insights into the current landscape of susceptibility to antimalarial drugs and molecular markers of resistance in P. falciparum isolates from West and Central Africa. While the data suggests that ACTs and sulfadoxine-pyrimethamine are likely to be effective in these regions, the phenotypic changes we observed call for intensifying the monitoring of antimalarial drug resistance in Africa.